Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), is crucial. This strategy aims to reduce HIV transmission and control new infections. The 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland, from October 18 to 20, 2023. At the conference, Professor Jean-Michel Molina from the University of Paris City, Saint Louis and Lariboisière Hospital, shared insights on the application and challenges of HIV PrEP and PEP.

Progress and Challenges in the Field of HIV/AIDS – The 19th EACS Conference Concludes Successfully

The 19th European AIDS Conference (EACS 2023), a highly anticipated event in the field of HIV/AIDS, was held grandly in Warsaw, Poland, from October 18 to 20, 2023. The conference provided a robust platform for medical professionals and researchers in the HIV/AIDS field, facilitating a comprehensive and multi-faceted discussion on urgent issues in combating HIV/AIDS. It showcased numerous breakthrough clinical studies and honored outstanding contributors in the field. The conference offered a thorough and in-depth interpretation of the current status and future vision of global HIV/AIDS prevention and treatment.

What to start with? A review of current guidelines (EACS, WHO, DHHS)

Hello. My name is Cristiana Oprea. I'm an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also part of the EuroSida steering committee since 2017.

Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients

This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment of HIV does not increase the risk of cardiovascular events.